Semaglutide’s diabetes label — 0.5/1/2 mg weekly — with cardiovascular benefit proven in SUSTAIN-6 (HR 0.74) and a chronic-kidney-disease indication added in 2025 on FLOW’s 24% result. Never labeled for weight, however the culture talks.
Deeper data: the trial index holds every figure above with sources; same drug, two labels, the coverage logic.
Ozempic is the household name — and, strictly, a type 2 diabetes drug. Its weight effects made it famous; its label is about glucose, cardiovascular risk in diabetes, and, more recently, kidney disease.
Indications and evidence
Glycemic control in type 2 diabetes and cardiovascular risk reduction in adults with diabetes and established heart disease (SUSTAIN-6). Following the FLOW trial’s kidney-outcome results, an indication covering chronic kidney disease risk in diabetes was added in early 2025 — verify current label text. Weekly doses: 0.5, 1, and 2 mg after a 0.25 mg starter month.
The off-label weight reality
Ozempic’s maximum dose is 2 mg — below Wegovy’s 2.4 mg — and its trials targeted people with diabetes, so “Ozempic for weight loss” borrows evidence from its sibling label. Off-label prescribing is legal; insurance increasingly polices it, and supply pressure on diabetes patients was a defining controversy of the shortage years. Anyone whose goal is weight management is better matched to the Wegovy file.
Safety essentials
See the molecule page. In diabetes combinations, reduce-and-monitor rules around insulin and sulfonylureas apply. Long-term diabetic retinopathy monitoring guidance in the label deserves attention it rarely gets in consumer coverage.
The shortage legacy
Ozempic’s cultural moment had a cost: the 2022–2024 shortage years pitted off-label weight-loss demand against diabetes patients who needed the drug for glucose control, spawned the compounding boom our legal file documents, and left a durable gray market our warning file covers. Supply normalized, but the episode explains why regulators now police “compounded semaglutide” claims aggressively.
Costs in practice
List price runs high (verify current); insured diabetes patients commonly pay far less, and the manufacturer savings card assists the commercially insured. Cash payers seeking semaglutide for weight are usually better matched to Wegovy’s self-pay channel or the verified compounded flat rates in the ledger than to cash-price Ozempic — same molecule, worse cash math.
Who it fits
People with type 2 diabetes — full stop — especially with cardiovascular disease or kidney involvement, where its outcome evidence is unmatched in the semaglutide family. It is the wrong door for pure weight management, not because the molecule differs but because the label, doses, and coverage logic all do.
Practical dosing notes
The pen delivers 0.25/0.5 mg or 1 mg or 2 mg depending on the device; a missed weekly dose can be taken within 5 days per the label, otherwise skip to the next scheduled one. Injection-site rotation and refrigeration-then-room-temperature handling rules are in the medication guide — small logistics that prevent large frustrations.
References
Ozempic prescribing information — novo-pi.com. SUSTAIN-6, NEJM 2016; FLOW kidney outcomes — see organ-evidence file.